Defendant
1 case as defendant.
Celgene Corporation is a biopharmaceutical company headquartered in Summit, New Jersey, founded in 1980 (incorporated 1986). It was formerly listed on Nasdaq (ticker: CELG) and was acquired by Bristol Myers Squibb (BMS; NYSE: BMY) in a roughly $74 billion cash-and-stock transaction announced January 2019 and closed in November 2019. Celgene now operates as a wholly owned BMS subsidiary and has no separate public listing; Investing.com's profile lists about 8,850 employees. Combined BMS revenue is roughly $48 billion (2024), so no standalone revenue figure is current.
Operations. Celgene discovers, develops, and commercializes therapies for cancer and inflammatory/immune diseases. Its principal marketed products are the multiple-myeloma drugs Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), and Thalomid (thalidomide), plus Abraxane (paclitaxel protein-bound particles). Its pipeline includes CAR-T assets acquired with Juno Therapeutics (2018). Otezla was divested to Amgen in 2019 as a merger condition. Celgene is an operating company, not a non-practicing entity.
Litigation posture. The tracked data shows Celgene as a defendant in 1 case and plaintiff in 0, consistent with an operating pharmaceutical company defending against third-party claims rather than a patent assertion entity. The single tracked matter is a 2025 antitrust action by an insurer/payor over branded-drug pricing and patent practices — not a conventional patent-infringement suit. No Eastern District of Texas clustering appears; the tracked jurisdiction is D.N.J., though the public docket for the Cigna case below shows S.D.N.Y.
Notable case. The Cigna Group v. Celgene Corp. (BMS) (filed June 24, 2025; publicly docketed as No. 1:25-cv-05237, S.D.N.Y.). Cigna alleges Celgene and BMS monopolized pomalidomide (Pomalyst) through a "pay-for-delay" reverse-payment scheme, fraudulently obtained patents, and sham litigation against generics including Teva, Natco, and Aurobindo, seeking treble damages and injunctive relief. Related payor antitrust litigation over Revlimid/Thalomid has also proceeded. Celgene/BMS disputes the claims; no merits ruling is implied here.
Sources: BMS/Celgene merger press coverage (Reuters, Bloomberg, AP); GlobalData SWOT via Research and Markets; Investing.com company profile; Law360, Reuters, and dockets.justia.com case records.
Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; The Cigna Group sued Celgene in D.N.J. Status is generally pending/consolidated.